For Praxis Precision Medicines Inc. [PRAX], Analyst sees a rise to $4. What next?

Praxis Precision Medicines Inc. [NASDAQ: PRAX] plunged by -$1.92 during the normal trading session on Friday and reaching a high of $1.58 during the day while it closed the day at $1.00. The company report on March 3, 2023 that Praxis Precision Medicines to Present at Upcoming Investor Conferences.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in the following upcoming investor conferences:.

Praxis Precision Medicines Inc. stock has also loss -70.16% of its value over the past 7 days. However, PRAX stock has declined by -54.91% in the 3 months of the year. Over the past six months meanwhile, it has lost -68.06% and lost -58.13% year-on date.

The market cap for PRAX stock reached $152.92 million, with 47.61 million shares outstanding and 46.80 million shares in the current float. Compared to the average trading volume of 1.04M shares, PRAX reached a trading volume of 34369350 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Praxis Precision Medicines Inc. [PRAX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PRAX shares is $10.12 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PRAX stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Wedbush have made an estimate for Praxis Precision Medicines Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on June 06, 2022. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on December 16, 2021, representing the official price target for Praxis Precision Medicines Inc. stock. Previously, the target price had yet another raise to $28, while BofA Securities analysts kept a Buy rating on PRAX stock.

The Average True Range (ATR) for Praxis Precision Medicines Inc. is set at 0.42 The Price to Book ratio for the last quarter was 0.62, with the Price to Cash per share for the same quarter was set at 0.65.

PRAX stock trade performance evaluation

Praxis Precision Medicines Inc. [PRAX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -70.16. With this latest performance, PRAX shares dropped by -79.62% in over the last four-week period, additionally sinking by -68.06% over the last 6 months – not to mention a drop of -92.36% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PRAX stock in for the last two-week period is set at 14.27, with the RSI for the last a single of trading hit 6.50, and the three-weeks RSI is set at 21.87 for Praxis Precision Medicines Inc. [PRAX]. The present Moving Average for the last 50 days of trading for this stock 3.4580, while it was recorded at 2.6803 for the last single week of trading, and 3.2774 for the last 200 days.

Praxis Precision Medicines Inc. [PRAX]: An insightful look at the core fundamentals

Praxis Precision Medicines Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.20 and a Current Ratio set at 3.20.

Earnings per share (EPS) analysis for Praxis Precision Medicines Inc. [PRAX] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PRAX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Praxis Precision Medicines Inc. go to -14.60%.

Praxis Precision Medicines Inc. [PRAX]: Insider Ownership positions

There are presently around $45 million, or 90.30% of PRAX stock, in the hands of institutional investors. The top three institutional holders of PRAX stocks are: BLACKSTONE INC. with ownership of 4,894,109, which is approximately 0% of the company’s market cap and around 0.60% of the total institutional ownership; EVENTIDE ASSET MANAGEMENT, LLC, holding 3,518,062 shares of the stock with an approximate value of $3.51 million in PRAX stocks shares; and BLACKROCK INC., currently with $2.96 million in PRAX stock with ownership of nearly -8.398% of the company’s market capitalization.

47 institutional holders increased their position in Praxis Precision Medicines Inc. [NASDAQ:PRAX] by around 9,984,841 shares. Additionally, 63 investors decreased positions by around 6,527,405 shares, while 19 investors held positions by with 29,106,104 shares. The mentioned changes placed institutional holdings at 45,618,350 shares, according to the latest SEC report filing. PRAX stock had 20 new institutional investments in for a total of 4,665,325 shares, while 22 institutional investors sold positions of 866,362 shares during the same period.


Please enter your comment!
Please enter your name here